Top

Published in:

01-10-2019 | Metastasis | Research Paper

Factors related to the quality of life in patients with bone metastases

Authors: Yusuke Shinoda, Ryoko Sawada, Futaba Yoshikawa, Takahiro Oki, Toshihide Hirai, Hiroshi Kobayashi, Ko Matsudaira, Hiroyuki Oka, Sakae Tanaka, Hirotaka Kawano, Nobuhiko Haga

Published in: Clinical & Experimental Metastasis | Issue 5/2019

Abstract

Treatment for bone metastases aims to preserve patients’ quality of life (QOL). Therefore, assessment of patients’ reported QOL is important, especially in this field. This cross-sectional study sought to investigate the clinical factors of QOL in patients with bone metastasis in different cancer settings, at any treatment status, and examined the effect of these factors on systemic symptoms and psychological disorders. This study was conducted by a multidisciplinary team for bone metastases at a university hospital in Japan. One-hundred seventy-four patients who could complete the self-report questionnaires were selected. The questionnaire included the EQ-5D, EORTC QLQ-C15-PAL, BM22, and K6 distress scale. We obtained clinical data on tumor progression, bone metastasis, pain, and ECOG-PS. The mean (SD) EQ-5D score was 0.58 (0.24), which was lower than that of the general Japanese and US population (0.85). Skeletal-related events (SREs), pain, and ECOG-PS were significantly related to lower EQ-5D scores in the multivariable analysis (p < 0.01), whereas primary lesion or expected prognosis at the first examination was not. These three factors were also related to systemic symptoms and emotional functioning. Radiologically lytic bone metastasis and lower limb/acetabular metastases were related to SREs and ECOG-PS, respectively. In conclusion, for improving the QOL of patients with bone metastases, we should focus on SRE prevention, treatment for pain, and modifying ADL, and a multidisciplinary team might be useful.

Available only for authorised users

Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388CrossRefPubMed

Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330CrossRefPubMed

Hage WD, Aboulafia AJ, Aboulafia DM (2000) Incidence, location, and diagnostic evaluation of metastatic bone disease. Orthop Clin N Am 31:515–528CrossRef

Hosono N, Yonenobu K, Fuji T, Ebara S, Yamashita K, Ono K (1995) Orthopaedic management of spinal metastases. Clin Orthop Relat Res 312:148–159

Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–167CrossRefPubMed

Zeng L, Chow E, Bedard G et al (2012) Quality of life after palliative radiation therapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ-BM22. Int J Radiat Oncol Biol Phys 84(3):e337–e342CrossRefPubMed

Caissie A, Zeng L, Nguyen J et al (2012) Assessment of health-related quality of life with the European Organization for Research and Treatment of Cancer QLQ-C15-PAL after palliative radiotherapy of bone metastases. Clin Oncol 24(2):125–133CrossRef

Badia X, Schiaffino A, Alonso J, Herdman M (1998) Using the EuroQol 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res 7:311–322CrossRefPubMed

Katagiri H, Okada R, Takagi T, Takahashi M, Murata H, Harada H, Nishimura T, Asakura H, Ogawa H (2014) New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med 3(5):1359–1367CrossRefPubMedPubMedCentral

10.

Groenvold M, Petersen MA, Aaronson NK et al (2006) The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 42(1):55–64CrossRefPubMed

11.

Chow E, Hird A, Velikova G et al (2009) The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer 45(7):1146–1152CrossRefPubMed

12.

Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, Walters EE, Zaslavsky AM (2002) Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med 32(6):959–976CrossRefPubMed

13.

van Roij J, Fransen H, van de Poll-Franse L, Zijlstra M, Raijmakers N (2018) Measuring health-related quality of life in patients with advanced cancer: a systematic review of self-administered measurement instruments. Qual Life Res 27(8):1937–1955CrossRefPubMed

14.

Yamada K, Matsudaira K, Takeshita K, Oka H, Hara N, Takagi Y (2014) Prevalence of low back pain as the primary pain site and factors associated with low health-related quality of life in a large Japanese population: a pain-associated cross-sectional epidemiological survey. Mod Rheumatol 24(2):343–348CrossRefPubMed

15.

van der Vliet QM, Pereira NP, Janssen SJ, Hornicek FJ, Ferrone ML, Bramer JA, van Dijk CN, Schwab JH (2017) What factors are associated with quality of life, pain interference, anxiety, and depression in patients with metastatic bone disease? Clin Orthop Relat Res 475(2):498–507CrossRefPubMed

16.

McCabe RM, Grutsch JF, Nutakki SB, Braun DP, Markman M (2014) Can quality of life assessments differentiate heterogeneous cancer patients? PLoS ONE 9(6):e99445. https://doi.org/10.1371/journal.pone.0099445 CrossRefPubMedPubMedCentral

17.

McDonald R, Ding K, Chow E et al (2016) Classification of painful bone metastases as mild, moderate, or severe using both EORTC QLQ-C15-PAL and EORTC QLQ-BM22. Support Care Cancer 24(12):4871–4878CrossRefPubMed

18.

Kunikane H, Yokota I, Katakami N et al (2019) Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13). Oncol Lett 17(1):1320–1326PubMed

19.

Rustøen T, Moum T, Padilla G, Paul S, Miaskowski C (2005) Predictors of quality of life in oncology outpatients with pain from bone metastasis. J Pain Symptom Manag 30(3):234–242CrossRef

20.

Manabe J, Kawaguchi N, Matsumoto S, Tanizawa T (2005) Surgical treatment of bone metastasis: indications and outcomes. Int J Clin Oncol 10(2):103–111CrossRefPubMed

21.

Ruff RL, Ruff SS, Wang X (2007) Persistent benefits of rehabilitation on pain and life quality for nonambulatory patients with spinal epidural metastasis. J Rehabil Res Dev 44(2):271–278CrossRefPubMed

22.

Kimura T (2018) Multidisciplinary approach for bone metastasis: a review. Cancers. https://doi.org/10.3390/cancers10060156 CrossRefPubMedPubMedCentral

23.

Lipton A, Fizazi K, Stopeck AT et al (2016) Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer 53:75–83CrossRefPubMed

24.

Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458–1468CrossRefPubMed

25.

Vassiliou V, Kalogeropoulou C, Petsas T, Leotsinidis M, Kardamakis D (2007) Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between clinical status of patients and type of bone metastases? Clin Exp Metastasis 24(1):49–56CrossRefPubMed

Title: Factors related to the quality of life in patients with bone metastases
Authors: Yusuke Shinoda
Ryoko Sawada
Futaba Yoshikawa
Takahiro Oki
Toshihide Hirai
Hiroshi Kobayashi
Ko Matsudaira
Hiroyuki Oka
Sakae Tanaka
Hirotaka Kawano
Nobuhiko Haga
Publication date: 01-10-2019
Publisher: Springer Netherlands
Keywords: Metastasis
Bone Metastasis
Published in: Clinical & Experimental Metastasis / Issue 5/2019
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-019-09983-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

The prognostic impact of lymph node metastasis in patients with non-small cell lung cancer and distant organ metastasis

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer

Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells

Quantification of PpIX-fluorescence of cerebral metastases: a pilot study

Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC

Keynote webinar | Spotlight on antibody–drug conjugates in cancer